Table 3 Recurrent chromosomal translocations involving ALK in cancers
From: Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies
Chromosomal translocation | Partner protein | Frequency (%) | Fusion protein (kDa) | Cellular localization | Type of tumor | Refs |
|---|---|---|---|---|---|---|
t(2;5)(p23;q35) | Nucleophosmin (NPM) | 75–80 | NPM–ALK (80) | Nucleus, mucleolus and cytoplasm | ALK+ ALCL and ALK+ DLBCL | |
t(1;2)(q25;p23) | Tropomyosin 3 (TPM3) | 12–18 | TPM3–ALK (104) | Cytoplasm | ALK+ ALCL and IMT | |
t(2;3)(p23;q21) | TRK-fused gene (TFG) | 2 | TFG–ALK (113,97,85) | Cytoplasm | ALK+ ALCL | |
inv(2)(p23;q35) | ATIC | 2 | ATIC–ALK (96) | Cytoplasm | ALK+ ALCL and IMT | |
t(2;17)(p23;q23) | Clathrin heavy chain-like 1 (CLTC1) | 2 | CLTC1–AKL (250) | Granular cytoplasmic | ALK+ ALCL, IMT and ALK+ DLBCL | |
t(2;X)(p23;q11–12) | Moesin (MSN) | <1 | MSN–ALK (125) | Cell-membrane associated | ALK+ ALCL | |
t(2;19)(p23;p13) | Tropomyosin 4 (TPM4) | <1 | TPM4–ALK (95-105) | Cytoplasm | ALK+ ALCL and IMT | |
t(2;17)(p23;q25) | ALO17 | <1 | ALO17–ALK (ND) | Cytoplasm | ALK+ ALCL | |
t(2l2)(p23;q13) or inv(2)(p23;q11–13) | RAN-binding protein 2 (RANBP2) | <1 | RANBP2–ALK (160) | Periphery of the nucleus | IMT | |
t(2;22)(p23;q11.2) | Non-muscle myosin heavy chain (MYH9) | <1 | MYH9–ALK (220) | Cytoplasm | ALK+ ALCL | |
t(2;11;2)(p23;p15;q31) | Cysteinyl-tRNA synthetase (CARS) | <1 | CARS–ALK (130) | Unknown | IMT | |
ins(3’ALK)(4q22–24) | Unknown | <1 | Unknown | Granular cytoplasmic | ALK+ DLBCL | |
t(2;4)(p23;q21) | SEC31 homologue A (S.cerevisiae) (SEC31L1) | <1 | SEC31L1–ALK (ND) | Cytoplasm | IMT | |
inv(2)(p21;p23) | Echinoderm microtubule-associated protein-like4 (EML4) | 6 | EML4–ALK (ND) | Unknown | NSCLC |
